This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
FORUM Pharmaceuticals, Inc.
Drug Names(s): EVP-0334
Description: EVP-0334 is an orally bioavailable histone deactylase inhibitor. These enzymes remove acetyl groups from histone proteins surrounding tightly coiled strands of DNA. Acetyl groups mark the DNA for unwinding so that genes can be exposed for transcription. By stopping the enzymes from working, EVP-0334 promotes a looser DNA structure and thus more gene expression.
On February 6, 2008 MethylGene and EnVivo Pharmaceuticals announced that MethylGene exercised its right to opt-out of further funding in its collaboration with EnVivo signed in February 2005. EnVivo will continue to research and develop histone deacetylase (HDAC) inhibitors for neurodegenerative disorders such as Huntingtons, Alzheimers and Parkinsons diseases under license from MethylGene. A lead compound has been identified during the collaboration and designated as a clinical candidate by EnVivo. MethylGene will receive royalties on net sales of any approved product as well as a share of any sublicense income from future partnerships EnVivo may enter into with other companies for neurodegenerative programs.
In June 2013, MethylGene and Mirati announced the successful completion, effective June 28, 2013 whereby Mirati Therapeutics, a holding company, has become the ultimate parent corporation of MethylGene and its subsidiaries.
Partners: Mirati Therapeutics
Additional information available to subscribers only: